Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer
Targeted therapy in NSCLC, FCS was part of this trial.
Targeted therapy in NSCLC, FCS was part of this trial.
Luspaterecpt before epoetin in low grade MDS patients.
Pembrolizumab in lymphoma, this is not a common one, usually in young females, could be hard to treat.
For our radiation oncology colleagues, any comments? For oligometastases, radiation therapy helps improve survival when added to systemic therapy.
Combination PARP with androgen blocker, regardless of HRR gene alterations showed benefit vs. androgen blocker alone.
High burden prostate cancer patients benefit form androgen deprivation and Taxotere combination.
CAR-T for second line is better than standard of care, the question is: how about compared to BITE therapy? Future is exciting for those patients.
Paradigm shift in rectal cancer therapy? Some may not need surgery, now some may not need radiotherapy.